Nexavar Effective in Advanced HCC: Phase III Trial Stopped
WEST HAVEN, ConnecticutBayer and Onyx (Emeryville, California) have stopped the phase III SHARP trial of sorafenib (Nexavar) in patients with advanced hepatocellular carcinoma (HCC), based on the recommendation of an independent monitoring committee after interim data showed that the trial had met its primary endpoint. Patients in the Nexavar arm achieved a "superior overall survival," compared to those in the placebo arm, and adverse events were similar in both arms, the companies said in a press release. All patients enrolled in the trial are now being given access to Nexavar.
Sintilimab Combo Shows Modest Efficacy, Safety in HER2– Gastric/GEJ Cancer
February 18th 2024Over half of the patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma achieve a major pathological complete response following treatment with sintilimab plus FLOT in a phase 2 trial.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
Fruquintinib/Paclitaxel Improves PFS, ORR in Gastric/GEJ Adenocarcinoma
February 7th 2024Findings from the FRUTIGA study support fruquintinib plus paclitaxel as a promising second-line treatment for those with advanced gastric or gastroesophageal junction adenocarcinoma following prior chemotherapy.